Results 91 to 100 of about 115,857 (367)
ING4 (inhibitor of growth family, member 4) [PDF]
, 2011 Review on ING4 (inhibitor of growth family, member 4), with data on DNA, on the protein encoded, and where the gene is ...
Greco, A, Miranda, C
core +1 more source
Targeted Therapies in Myelofibrosis: Present Landscape, Ongoing Studies, and Future Perspectives
American Journal of Hematology, EarlyView.ABSTRACT Myelofibrosis (MF) is a myeloproliferative neoplasm that is accompanied by driver JAK2, CALR, or MPL mutations in more than 90% of cases, leading to constitutive activation of the JAK–STAT pathway. MF is a multifaceted disease characterized by trilineage myeloid proliferation with prominent megakaryocyte atypia and bone marrow fibrosis, as ...
Giuseppe G. Loscocco, Paola Guglielmelli
wiley +1 more source
No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML 10 and 12 trials [PDF]
, 2005 Fetal liver tyrosine kinase 3 (FLT3) internal tandem duplications (ITDs) are powerful adverse prognostic indicators for relapse in acute myelold leukemia (AML) but the most efficacious therapy for FLT3/ ITD+ patients is currently unknown.
Burnett, AK +6 more
core
American Journal of Hematology, EarlyView.ABSTRACT Allogeneic hematopoietic stem‐cell transplantation (HCT) remains the only potentially curative therapy for patients with myelodysplastic neoplasms (MDS) and myelofibrosis (MF) and is the standard care for eligible patients with higher‐risk disease. Despite significant advancements, both diseases pose unique challenges due to their clinical and
Nico Gagelmann, Nicolaus Kröger
wiley +1 more source
Immunophenotypes of Acute Myeloid Leukemia From Flow Cytometry Data Using Templates [PDF]
arXiv, 2014 Motivation: We investigate whether a template-based classification pipeline could be used to identify immunophenotypes in (and thereby classify) a heterogeneous disease with many subtypes. The disease we consider here is Acute Myeloid Leukemia, which is heterogeneous at the morphologic, cytogenetic and molecular levels, with several known subtypes. The
arxiv
DLBCL-Morph: Morphological features computed using deep learning for an annotated digital DLBCL image set [PDF]
arXiv, 2020 Diffuse Large B-Cell Lymphoma (DLBCL) is the most common non-Hodgkin lymphoma. Though histologically DLBCL shows varying morphologies, no morphologic features have been consistently demonstrated to correlate with prognosis. We present a morphologic analysis of histology sections from 209 DLBCL cases with associated clinical and cytogenetic data ...
arxiv
American Journal of Hematology, EarlyView.ABSTRACT In the Phase 3 DREAMM‐7 study of patients with relapsed/refractory multiple myeloma (RRMM) who received ≥ 1 prior therapy, belantamab mafodotin plus bortezomib and dexamethasone (BVd) demonstrated a progression‐free survival (PFS) benefit versus daratumumab plus bortezomib and dexamethasone (DVd).
Joshua Richter +13 more
wiley +1 more source
Cytogenetics of Legumes in the Phaseoloid Clade
The Plant Genome, 2013 Cytogenetics played an essential role in studies of chromosome structure, behavior, and evolution in numerous plant species. The advent of molecular cytogenetics combined with recent development of genomic resources has ushered in a new era of chromosome
Aiko Iwata +2 more
doaj +1 more source
Genetic diversity at the FMR1 locus in the Indonesian population [PDF]
, 2000 We report an analysis of allelic diversity at short tandem repeat polymorphisms within the fragile XA locus in 1069 male volunteers from twelve Indonesian sub-populations.
Buckley, Michael F +6 more
core +1 more source
Topics of Interest in Women With Myeloproliferative Neoplasms
American Journal of Hematology, EarlyView.Women with MPN: life‐cycle phases, specific risks, and influencing factors. ABSTRACT Overview Sex and gender have emerged as central modifiers of disease biology, phenotype, and clinical outcomes in myeloproliferative neoplasms (MPNs). This review will uniquely highlight issues affecting women with MPN and articulate their relevant determinants ...
Natasha Szuber +2 more
wiley +1 more source